CN1688343B - 修饰糖、其缀合物及其制备方法 - Google Patents

修饰糖、其缀合物及其制备方法 Download PDF

Info

Publication number
CN1688343B
CN1688343B CN038237245A CN03823724A CN1688343B CN 1688343 B CN1688343 B CN 1688343B CN 038237245 A CN038237245 A CN 038237245A CN 03823724 A CN03823724 A CN 03823724A CN 1688343 B CN1688343 B CN 1688343B
Authority
CN
China
Prior art keywords
sugar
group
capsular saccharides
protein
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038237245A
Other languages
English (en)
Chinese (zh)
Other versions
CN1688343A (zh
Inventor
A·吉亚诺齐
G·阿弗拉尼
F·诺莱利
P·科斯坦蒂诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Novartis Vaccines and Diagnostics SRL
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL, Chiron SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of CN1688343A publication Critical patent/CN1688343A/zh
Application granted granted Critical
Publication of CN1688343B publication Critical patent/CN1688343B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN038237245A 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法 Expired - Fee Related CN1688343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
GB0220198.6 2002-08-30
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101825535A Division CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Publications (2)

Publication Number Publication Date
CN1688343A CN1688343A (zh) 2005-10-26
CN1688343B true CN1688343B (zh) 2010-09-08

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038237245A Expired - Fee Related CN1688343B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法
CN2010101825535A Expired - Fee Related CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101825535A Expired - Fee Related CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN1688343B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863998B (zh) * 2002-08-30 2012-08-29 诺华疫苗和诊断有限公司 修饰糖、其缀合物及其制备方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN107810273B (zh) * 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX2021010555A (es) * 2019-03-08 2022-04-06 Glaxosmithkline Biologicals Sa Derivados carbocíclicos y derivados conjugados de los mismos y su uso en vacunas.
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
NZ331578A (en) 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
DE69737298T2 (de) * 1997-08-08 2007-06-28 Dade Behring Marburg Gmbh Konjugate von polysacchariden und biomolekülen
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863998B (zh) * 2002-08-30 2012-08-29 诺华疫苗和诊断有限公司 修饰糖、其缀合物及其制备方法

Also Published As

Publication number Publication date
WO2004019992A1 (en) 2004-03-11
JP2006511465A (ja) 2006-04-06
JP2012017342A (ja) 2012-01-26
RU2531909C2 (ru) 2014-10-27
EP1534342A1 (en) 2005-06-01
NZ538703A (en) 2006-09-29
ES2260682T3 (es) 2006-11-01
US20150166593A1 (en) 2015-06-18
DE60303961D1 (de) 2006-05-04
CN101863998B (zh) 2012-08-29
JP5268222B2 (ja) 2013-08-21
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
BR0314089A (pt) 2005-11-16
US20060263390A1 (en) 2006-11-23
JP5314745B2 (ja) 2013-10-16
DE60303961T2 (de) 2006-10-26
AU2003260921B2 (en) 2008-03-06
DK1534342T3 (da) 2006-07-10
RU2008150551A (ru) 2010-06-27
CA2497167A1 (en) 2004-03-11
CN1688343A (zh) 2005-10-26
ATE319481T1 (de) 2006-03-15
EP1534342B1 (en) 2006-03-08
US8895516B2 (en) 2014-11-25
GB0220198D0 (en) 2002-10-09
CA2497167C (en) 2011-07-12
CN101863998A (zh) 2010-10-20
RU2005108992A (ru) 2005-11-10

Similar Documents

Publication Publication Date Title
CN101863998B (zh) 修饰糖、其缀合物及其制备方法
EP1777236B1 (en) Modified saccharides having improved stability in water for use as a medicament
EP2184071B1 (en) Capsular polysaccharide solubilisation and combination vaccines
EP1587538B1 (en) Mucosal meningococcal vaccines
EP2258717A2 (en) Variant form of meningococcal NadA
CN100491403C (zh) 具有改善的水中稳定性的修饰的糖类
AU2003216633B2 (en) Modified saccharides having improved stability in water

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20170728

Address after: Belgium Sutter Rixon

Patentee after: Glazo Smithkline Beecham Biologicals S. A.

Address before: Italy Siena

Patentee before: Novartis Vaccines & Diagnostic

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100908

Termination date: 20180901

CF01 Termination of patent right due to non-payment of annual fee